However, Li and team, who initiated the DESTINY-Lung 01 trial, have included HER2-mutated/HER2-negative metastatic BC in their ongoing clinical trial on the efficacy and safety of T-DXd for the treatment of advanced solid tumors with activating HER2 mutations (DESTINY-PanTumor01 trial number NCT04639219). Here, ERBB2 is linked to breast cancer.